Please assess the completion status of the following clinical trial:

Trial Title: A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed and histologically confirmed glioblastoma multiforme~* Tumor must be surgically accessible and tissue must be available~* Age ≥ 20 years and \< 75 years~* Life expectancy ≥ 6 months~* Baseline MRI images must be done within 2 days after surgery~* Patients must have a Karnofsky performances score ≥ 60 prior to treatment.~* Patients must not have received prior cytotoxic drug therapy, non-cytotoxic drug therapy, or experimental drug therapy for brain tumors.~* Adequate hematologic (absolute neutrophil count (ANC) ≥ 1.5x109/L, platelet count ≥ 100x109/L, hemoglobin ≥ 10 g/dL ), renal (creatinine ≤ 1.25xULN ), and hepatic function (total bilirubin ≤ 1.5xULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5xULN)~* Women with childbearing potential must have a negative serum pregnancy test less than 7 days prior to the first dose of study drug.~* Both men and women of reproductive potential agree to use approved contraception, such as condom and placement of an intrauterine device (IUD), during the study and until 3 months after the discontinuation of study treatment.~* Willing and able to comply with the protocol as judged by the investigator~* Patients must provide written consent~Exclusion Criteria:~* Any prior chemotherapy (including carmustine-containing wafers) or immunotherapy (including vaccine therapy )~* Any prior radiotherapy to the brain~* Any concurrent malignancy other than basal cell carcinoma or carcinoma in situ of the cervix. Patients with a previous malignancy but without evidence of disease for ≥ 5 years will be allowed to enter the trial~* Any contraindication to TMZ listed in the local label~* Low-grade astrocytoma~* Unable to undergo MRI~* Past medical history of disease with poor prognosis according to the judgment of the Investigator~* HIV infection~* Patients with positive anti-HCV~* Patients with positive HbsAG who received any related treatment within the past 6 months~* Patients suffering from hereditary fructose intolerance (HFI).~* Patients receive any investigational agent(s) or device(s) within 30 days prior to entering the study~* Known coronary artery disease, significant arrhythmias or severe congestive heart failure

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CAN008 (Type: EXPERIMENTAL): CAN008 administered as a 30 min intravenous infusion once a week until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).